Diaceutics PLC (LON:DXRX) Insider Jordan Clark Buys 104 Shares

Diaceutics PLC (LON:DXRX - Get Free Report) insider Jordan Clark bought 104 shares of the business's stock in a transaction dated Tuesday, January 28th. The stock was acquired at an average price of GBX 144 ($1.77) per share, for a total transaction of £149.76 ($184.00).

Diaceutics Stock Performance

Shares of LON:DXRX traded down GBX 1.29 ($0.02) during mid-day trading on Monday, reaching GBX 134.96 ($1.66). The company had a trading volume of 84,576 shares, compared to its average volume of 154,666. The company has a current ratio of 4.85, a quick ratio of 9.92 and a debt-to-equity ratio of 2.93. The firm has a market cap of £114.00 million, a price-to-earnings ratio of -4,498.67 and a beta of 0.58. The company's 50-day moving average price is GBX 130.24 and its 200-day moving average price is GBX 128.60. Diaceutics PLC has a one year low of GBX 92.24 ($1.13) and a one year high of GBX 151 ($1.86).

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the company. Canaccord Genuity Group restated a "buy" rating and issued a GBX 160 ($1.97) target price on shares of Diaceutics in a research note on Tuesday, December 17th. Canaccord Genuity Group restated a "buy" rating and issued a GBX 160 ($1.97) target price on shares of Diaceutics in a research note on Tuesday, December 17th.

Diaceutics Company Profile

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.